BioNTech Results Presentation Deck

Potential To Tackle Multiple Diseases With Different Therapeutic Modalities iNeST / Fix Vac mRNA Cancer Vaccines Induces multi-specificity, multi-valency, high tumor-antigen specific cell responses with unprecedented potency . 4 Phase 2 randomized trials (2 iNeST and 2 Fix Vac) Cell Therapies Next Gen CAR-T Cell / Neoantigen-based T Cell / Personalized TCR-T Cell Therapy ● 2 Phase 1 FIH trials started in Feb. and Apr. 2021 ● Targeting Cancer Targeted Cancer Antibodies ● Antibodies Novel cancer cell surface targets for underserved high medical need cancers CA 19-9 antibody in 1L pancreatic cancer in Phase 1/2 trial Immunomodula Small Molecule Immunomodulators TLR-7 Agonist ● Potently modulates innate immunity Phase 1 trial Clinical progress across all platforms ● Bispecifics / Hexabody Next-generation checkpoint inhibitors to address a broad range of cancers Phase 1/2 trials of 2 bispecific antibodies ● ● Next Generation Immunomodulators Ribocytokines, RiboMabs mRNA encoded cytokines or antibodies with potential for improved properties and half life Potential to amplify vaccines and CPIs . 2 Phase 1 FIH Ribocytokine trials 18 CAR, Chimeric antigen receptor; TCR, T Cell receptor; FIH, First-in-human; CA 19-9: Cancer antigen 19-9; 1L, first-line; TLR-7, Toll-like receptor 7; CPI, Check-point Inhibitor Ribologicals BIONTECH

View entire presentation